US Patent

US10130636 — High dosage strength tablets of rucaparib

Method of Use · Assigned to Clovis Oncology Inc · Expires 2035-08-17 · 9y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a tablet formulation of the high dosage strength of rucaparib camsylate.

USPTO Abstract

A tablet including high dosage of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one camsylate salt has been disclosed.

Drugs covered by this patent

rucaparib-camsylate (RUCAPARIB CAMSYLATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2273`	—	rucaparib-camsylate
`U-2101`	—	rucaparib-camsylate
`U-2101`	—	rucaparib-camsylate

Patent Metadata

Patent number: US10130636
Jurisdiction: US
Classification: Method of Use
Expires: 2035-08-17
Drug substance claim: No
Drug product claim: No
Assignee: Clovis Oncology Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.